Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-25

Study Completion Date

2029-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Blood disorders like sickle cell disease and malaria affect many people around the world. Researchers want to learn more about blood disorders. To do this, they need to collect biological samples from people with blood disorders. They also need to collect samples from healthy people.

Objective:

To collect samples to use for research on blood disorders.

Eligibility:

People ages 18-70 who have blood disorders. Healthy volunteers without blood disorders are also needed.

Design:

Participants will be screened with a medical history, physical exam, and blood and urine tests.

Participants will give one or more samples. They will give them over 5 years. They can choose not to give any of the samples:

Saliva: Participants will spit into a tube. They may also have the inside of their mouth swabbed.

Urine: Participants will urinate into a cup.

Blood and blood waste products: Blood will be taken through a needle in the participant s arm.

Fat samples: An area on the participant s belly or buttock will be numbed. A small cut will be made into the skin and a small piece of fat removed.

Mucus and cells from the lungs: The participant will be sedated. A flexible tube will be inserted through the nose or mouth into the lung airways. These participants will also have a physical exam, chest x-ray, and heart tests after the procedure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research

NCT00277849

Hemoglobin Mutations Erythrocyte Variants

COMPLETED

Screening for Alpha Thalassemia in Healthy Volunteers

NCT02692872

Alpha Thalassemia

ACTIVE_NOT_RECRUITING

Blood Sampling for Research Related to Sickle Cell Disease

NCT00542230

Sickle Cell Trait Sickle Cell Disease Sickle Cell Anemia

RECRUITING

Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

NCT00047996

Sickle Cell Disease

ENROLLING_BY_INVITATION

Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases

NCT00840567

Anemia, Sickle Cell

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Physiology Unit of the Laboratory of Malaria and Vector Research studies the role of globin variants in erythroid and non-erythroid tissues. We hope to better understand the mechanism(s) through which alpha and beta globin variants impact malaria, sickle cell disease, or other diseases involving inflammation or vascular endothelial dysfunction.

The collection of human specimens from healthy volunteers and patients with malaria, sickle cell disease, or other diseases involving inflammation or endothelial dysfunction is necessary for the development of laboratory and physiological assays to further basic and clinical research studies. This protocol defines the purposes for which specimens will be collected and establishes general conditions under which sample collection will be performed. Development of assays and our research into the roles of alpha and beta globin in normal human physiology, as well as in the pathogenesis of malaria and sickle cell disease, requires laboratory analysis of saliva/buccal swab, urine, blood, blood waste products, adipose tissue, bronchial brushing, and/or bronchoalveolar lavage specimens from human volunteers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alpha and Beta Thalassemia Sickle Cell Disease Malaria Human Physiology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Healthy volunteers and patients with hematologic and hemolytic diseases, including alpha and beta globin variants, sickle cell disease, malaria, or other diseases involving inflammation or endothelial dysfunction.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged 18-70 years.
2. Able to provide informed consent.
3. Willing to allow biological samples to be stored for future research.
4. Willing to provide one or more of the following tissues: saliva, urine, blood, blood waste products, adipose tissue, bronchial brushing, and/or BAL samples.
5. Willing to allow genetic testing on collected biological samples.

Exclusion Criteria

1. Pregnancy.
2. Positive testing for hepatitis B virus, hepatitis C virus, or HIV (as determined by serum screening tests or relevant viral quantitative studies.)
3. Any condition that requires active medical intervention or monitoring to avert serious danger to the individual s health or wellbeing.
4. Any condition that, in the opinion of the PI, contraindicates participation in this study.

1\. Hemoglobin \< 10 g/dL for healthy female volunteers, \< 12 g/dL for healthy male volunteers, or \< 6 g/dL for participants with sickle cell disease or other chronic anemias.

Individuals meeting any of the following criteria will be excluded from undergoing adipose tissue biopsy. If the participant no longer meets any of these criteria at a later time, then they will be allowed to undergo this procedure.

1. Currently taking anticoagulation medication.
2. Platelets \< 100,000/microL.
3. History of keloid formation (or irregular fibrous tissue formed at the site of a scar or injury).
4. History of adverse reactions to lidocaine or other local anesthetics.
5. Any condition that, in the opinion of the PI, contraindicates this procedure.

Use of aspirin (or acetylsalicylic acid) and nonsteroidal anti-inflammatory drugs (NSAIDs) are permitted.

Individuals meeting any of the following criteria will be excluded from undergoing bronchoscopy. If the participant no longer meets any of these criteria at a later time, then they will be allowed to undergo this procedure.

1. Prothrombin time (PT) \> 1 second above the upper limit of normal (ULN) or international normalized ratio \> 1.3.
2. Partial thromboplastin time (PTT) \> 1 second above ULN.
3. Platelets \< 150,000/microL.
4. Currently taking anticoagulation medication.
5. Use of aspirin within 2 weeks of the bronchoscopy or NSAIDs within 2 days of the bronchoscopy.
6. Diagnosis of a pulmonary disorder (eg, asthma, chronic bronchitis, cystic fibrosis, or bronchiectasis).
7. Respiratory tract infection within the last 4 weeks.
8. History of adverse reactions to systemic and/or local anesthetics that will be used for this procedure.
9. History of cigarette smoking within the past 3 months.
10. History of chronic opioid use.
11. History of drug or alcohol abuse.
12. Post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 40% of predicted or pre-bronchodilator FEV1 \< 35% of predicted.
13. Active bronchospasm on physical examination.
14. History of lidocaine allergy.
15. Any condition that, in the opinion of the PI, contraindicates this procedure.

Co-enrollment guidelines: Participants may be co-enrolled in other studies. However, the PI must be notified of co-enrollment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes